This case demonstrates a favorable therapeutic response to adalimumab in monogenic IBD associated with TGFBR2 c.1583G>A and delineates serial endoscopic changes from the active to the treatment‐responsive phase. This evidence concerns the gene TGFBR2 and inflammatory bowel disease.